<DOC>
	<DOCNO>NCT00291902</DOCNO>
	<brief_summary>Study SB-681323 ( novel p38 MAPkinase inhibitor ) subject documented coronary heart disease ( CHD ) undergo elective percutaneous coronary intervention ( PCI ) .</brief_summary>
	<brief_title>A Pharmacokinetic Study Of SB-681323 In Subjects With Coronary Heart Disease Undergoing Percutaneous Intervention</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<criteria>Females must nonchildbearing potential . Female subject must negative pregnancy test . Subjects schedule undergo elective single vessel PCI perform within 6 week diagnostic coronary angiography . Must stable dose statin = 6 week prior screen , statin tolerability LDL &lt; 130 mg/dL ( 3.4 mmol/L ) Screening visit . Must capable providing inform consent . Have hsCRP concentration &gt; 2 mg/L , &lt; 10 mg/L screening . Women pregnant breast feeding . Planned PCI multivessel stenting . Planned PCI additional revascularization procedure stag different day study period . Planned PCI stenting ( e.g. , atherectomy , PTCA without stenting , etc ) . Planned PCI bypass graft . History CABG surgery . Planned cardiac major noncardiac surgery within study period . Disabling stroke past 6 month . History chronic viral hepatitis chronic hepatic disorder . History Gilbert 's syndrome elevate bilirubin concentration screen . History increase liver function test ( ALT , AST ) due acute chronic liver condition , upper limit normal screen past 6 month . Renal impairment serum creatinine &gt; 2.0 mg/dl ( 177umol/L ) Screening , history kidney transplant , history contrast nephropathy . Current inadequately control hypertension ( blood pressure &gt; 160 mmHg systolic and/or &gt; 100 mmHg diastolic ) stable dose antihypertensive medication . Current poorly control diabetes mellitus , define HbA1c &gt; 10 % Screening . History severe heart failure define NYHA class III IV know severe LV dysfunction ( EF &lt; 30 % ) regardless symptomatic status . History malignancy within past 5 year , nonmelanoma skin cancer . Current lifethreatening condition vascular disease may prevent subject complete study . Alcohol drug abuse within past 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>CHD</keyword>
	<keyword>coronary heart disease</keyword>
	<keyword>atherosclerosis</keyword>
	<keyword>inflammation</keyword>
</DOC>